Department of Cellular and Molecular Medicine, University of California, San Diego, School of Medicine, La Jolla, California, USA.
Nat Biotechnol. 2017 Mar;35(3):222-229. doi: 10.1038/nbt.3802. Epub 2017 Feb 27.
RNA-based therapeutics, such as small-interfering (siRNAs), microRNAs (miRNAs), antisense oligonucleotides (ASOs), aptamers, synthetic mRNAs and CRISPR-Cas9, have great potential to target a large part of the currently undruggable genes and gene products and to generate entirely new therapeutic paradigms in disease, ranging from cancer to pandemic influenza to Alzheimer's disease. However, for these RNA modalities to reach their full potential, they first need to overcome a billion years of evolutionary defenses that have kept RNAs on the outside of cells from invading the inside of cells. Overcoming the lipid bilayer to deliver RNA into cells has remained the major problem to solve for widespread development of RNA therapeutics, but recent chemistry advances have begun to penetrate this evolutionary armor.
基于 RNA 的治疗方法,如小干扰 (siRNAs)、微小 RNA (miRNAs)、反义寡核苷酸 (ASOs)、适体、合成 mRNA 和 CRISPR-Cas9,具有靶向目前大部分不可成药基因和基因产物的巨大潜力,并在疾病中产生全新的治疗模式,范围从癌症到大流行性流感再到阿尔茨海默病。然而,为了使这些 RNA 模式充分发挥其潜力,它们首先需要克服几十亿年来进化防御,使 RNA 一直处于细胞外,无法侵入细胞内。克服脂质双层将 RNA 递送到细胞内一直是广泛开发 RNA 治疗方法需要解决的主要问题,但最近的化学进展已开始突破这种进化防御。